{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:30:28Z","timestamp":1772199028010,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11584-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:44:42Z","timestamp":1772196282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-translational modifications: Principal regulators of bladder cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Zhiyuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"3","key":"11584_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"Cancer J Clin"},{"issue":"1","key":"11584_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D (2023) Bladder cancer. Nat reviews Disease primers 9(1):58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9","journal-title":"Nat reviews Disease primers"},{"issue":"19","key":"11584_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K (2020) Bladder Cancer: A Review. JAMA 324(19):1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","journal-title":"JAMA"},{"issue":"4","key":"11584_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Gurski LA (2024) NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024. J Natl Compr Cancer Network: JNCCN 22(4):216\u2013225. https:\/\/doi.org\/10.6004\/jnccn.2024.0024","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"11584_CR5","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q (2020) Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed pharmacotherapy = Biomedecine pharmacotherapie 129:110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"1","key":"11584_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10930-017-9696-z","volume":"36","author":"V Singh","year":"2017","unstructured":"Singh V, Ram M, Kumar R, Prasad R, Roy BK, Singh KK (2017) Phosphorylation: Implications in Cancer. Protein J 36(1):1\u20136. https:\/\/doi.org\/10.1007\/s10930-017-9696-z","journal-title":"Protein J"},{"issue":"1","key":"11584_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1124\/pharmrev.120.000082","volume":"73","author":"A Patwardhan","year":"2021","unstructured":"Patwardhan A, Cheng N, Trejo J (2021) Post-Translational Modifications of G Protein-Coupled Receptors Control Cellular Signaling Dynamics in Space and Time. Pharmacol Rev 73(1):120\u2013151. https:\/\/doi.org\/10.1124\/pharmrev.120.000082","journal-title":"Pharmacol Rev"},{"issue":"1","key":"11584_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee JM, Hammar\u00e9n HM, Savitski MM, Baek SH (2023) Control of protein stability by post-translational modifications. Nat Commun 14(1):201. https:\/\/doi.org\/10.1038\/s41467-023-35795-8","journal-title":"Nat Commun"},{"key":"11584_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.06.013","volume":"192","author":"LC Czuba","year":"2018","unstructured":"Czuba LC, Hillgren KM, Swaan PW (2018) Post-translational modifications of transporters. Pharmacol Ther 192:88\u201399. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.013","journal-title":"Pharmacol Ther"},{"issue":"6","key":"11584_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.tins.2020.03.011","volume":"43","author":"M Lemos Duarte","year":"2020","unstructured":"Lemos Duarte M, Devi LA (2020) Post-translational Modifications of Opioid Receptors. Trends Neurosci 43(6):417\u2013432. https:\/\/doi.org\/10.1016\/j.tins.2020.03.011","journal-title":"Trends Neurosci"},{"issue":"11","key":"11584_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.it.2021.09.005","volume":"42","author":"R Kumar","year":"2021","unstructured":"Kumar R, Theiss AL, Venuprasad K (2021) ROR\u03b3t protein modifications and IL-17-mediated inflammation. Trends Immunol 42(11):1037\u20131050. https:\/\/doi.org\/10.1016\/j.it.2021.09.005","journal-title":"Trends Immunol"},{"issue":"12","key":"11584_CR12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tplants.2018.09.004","volume":"23","author":"LD Vu","year":"2018","unstructured":"Vu LD, Gevaert K, De Smet I (2018) Protein Language: Post-Translational Modifications Talking to Each Other. Trends Plant Sci 23(12):1068\u20131080. https:\/\/doi.org\/10.1016\/j.tplants.2018.09.004","journal-title":"Trends Plant Sci"},{"issue":"3","key":"11584_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nchembio.2576","volume":"14","author":"R Aebersold","year":"2018","unstructured":"Aebersold R, Agar JN, Amster IJ, Baker MS, Bertozzi CR, Boja ES, Costello CE, Cravatt BF, Fenselau C, Garcia BA, Ge Y, Gunawardena J, Hendrickson RC, Hergenrother PJ, Huber CG, Ivanov AR, Jensen ON, Jewett MC, Kelleher NL, Kiessling LL, Zhang B (2018) How many human proteoforms are there? Nat Chem Biol 14(3):206\u2013214. https:\/\/doi.org\/10.1038\/nchembio.2576","journal-title":"Nat Chem Biol"},{"issue":"1","key":"11584_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341. https:\/\/doi.org\/10.1038\/nrc3817","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"11584_CR15","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1039\/d1cs00991e","volume":"51","author":"T Bilbrough","year":"2022","unstructured":"Bilbrough T, Piemontese E, Seitz O (2022) Dissecting the role of protein phosphorylation: a chemical biology toolbox. Chem Soc Rev 51(13):5691\u20135730. https:\/\/doi.org\/10.1039\/d1cs00991e","journal-title":"Chem Soc Rev"},{"issue":"1","key":"11584_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Hu K, Cai X, Yang B, He Q, Wang J, Weng Q (2022) Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sinica B 12(1):18\u201332. https:\/\/doi.org\/10.1016\/j.apsb.2021.07.023","journal-title":"Acta Pharm Sinica B"},{"issue":"4","key":"11584_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.7150\/ijbs.83774","volume":"20","author":"W Du","year":"2024","unstructured":"Du W, Tu S, Zhang W, Zhang Y, Liu W, Xiong K, Zhou F, Li N, Zhang R, Yu J, Li M, Xiang W, Qian K, Wang G, Xiao Y, Wang X, Ju L (2024) UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int J Biol Sci 20(4):1389\u20131409. https:\/\/doi.org\/10.7150\/ijbs.83774","journal-title":"Int J Biol Sci"},{"issue":"12","key":"11584_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s11010-022-04454-9","volume":"477","author":"MC Chen","year":"2022","unstructured":"Chen MC, Rajula A, Bharath Kumar S, Hsu V, Day CH, Chen CH, Wang RJ, Viswanadha TF, Li VP, C. C., Huang CY (2022) Tannic acid attenuate AKT phosphorylation to inhibit UMUC3 bladder cancer cell proliferation. Mol Cell Biochem 477(12):2863\u20132869. https:\/\/doi.org\/10.1007\/s11010-022-04454-9","journal-title":"Mol Cell Biochem"},{"issue":"24","key":"11584_CR19","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","volume":"83","author":"Y Ouyang","year":"2023","unstructured":"Ouyang Y, Ou Z, Zhong W, Yang J, Fu S, Ouyang N, Chen J, Xu L, Wu D, Qian J, Lin Y, Lin T, Huang J (2023) FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation. Cancer Res 83(24):4030\u20134046. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1065","journal-title":"Cancer Res"},{"key":"11584_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.humpath.2016.06.020","volume":"57","author":"PJ Hensley","year":"2016","unstructured":"Hensley PJ, Zetter D, Horbinski CM, Strup SE, Kyprianou N (2016) Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Hum Pathol 57:68\u201377. https:\/\/doi.org\/10.1016\/j.humpath.2016.06.020","journal-title":"Hum Pathol"},{"issue":"54","key":"11584_CR21","doi-asserted-by":"publisher","first-page":"92043","DOI":"10.18632\/oncotarget.20664","volume":"8","author":"F Wang","year":"2017","unstructured":"Wang F, Wu D, Fu H, He F, Xu C, Zhou J, Li D, Li G, Xu J, Wu Q, Chen J, Su L, Wang W, Zhang S (2017) Cofilin 1 promotes bladder cancer and is regulated by TCF7L2. Oncotarget 8(54):92043\u201392054. https:\/\/doi.org\/10.18632\/oncotarget.20664","journal-title":"Oncotarget"},{"key":"11584_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-13-45","volume":"13","author":"H Chung","year":"2013","unstructured":"Chung H, Kim B, Jung SH, Won KJ, Jiang X, Lee CK, Lim SD, Yang SK, Song KH, Kim HS (2013) Does phosphorylation of cofilin affect the progression of human bladder cancer? BMC Cancer 13:45. https:\/\/doi.org\/10.1186\/1471-2407-13-45","journal-title":"BMC Cancer"},{"issue":"12","key":"11584_CR23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.tips.2022.09.010","volume":"43","author":"A Orea-Soufi","year":"2022","unstructured":"Orea-Soufi A, Paik J, Bragan\u00e7a J, Donlon TA, Willcox BJ, Link W (2022) FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci 43(12):1070\u20131084. https:\/\/doi.org\/10.1016\/j.tips.2022.09.010","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"11584_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-020-0088-2","volume":"20","author":"G Calissi","year":"2021","unstructured":"Calissi G, Lam EW, Link W (2021) Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov 20(1):21\u201338. https:\/\/doi.org\/10.1038\/s41573-020-0088-2","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"11584_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-017-0664-1","volume":"16","author":"Z Liang","year":"2017","unstructured":"Liang Z, Wang X, Xu X, Xie B, Ji A, Meng S, Li S, Zhu Y, Wu J, Hu Z, Lin Y, Zheng X, Xie L, Liu B (2017) MicroRNA-608 inhibits proliferation of bladder cancer via AKT\/FOXO3a signaling pathway. Mol Cancer 16(1):96. https:\/\/doi.org\/10.1186\/s12943-017-0664-1","journal-title":"Mol Cancer"},{"issue":"8","key":"11584_CR26","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1002\/ctm2.263","volume":"10","author":"Y Chang","year":"2020","unstructured":"Chang Y, Jin H, Li H, Ma J, Zheng Z, Sun B, Lyu Y, Lin M, Zhao H, Shen L, Zhang R, Wu S, Lin W, Lu Y, Xie Q, Zhang G, Huang X, Huang H (2020) MiRNA-516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT\/FOXO3A\/SMURF1 axis. Clin translational Med 10(8):e263. https:\/\/doi.org\/10.1002\/ctm2.263","journal-title":"Clin translational Med"},{"issue":"5","key":"11584_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","volume":"6","author":"JY Fang","year":"2005","unstructured":"Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6(5):322\u2013327. https:\/\/doi.org\/10.1016\/S1470-2045(05)70168-6","journal-title":"Lancet Oncol"},{"issue":"11","key":"11584_CR28","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1158\/0008-5472.CAN-08-2816","volume":"69","author":"DC Tomlinson","year":"2009","unstructured":"Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA (2009) Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 69(11):4613\u20134620. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2816","journal-title":"Cancer Res"},{"issue":"10","key":"11584_CR29","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/2211-5463.12964","volume":"10","author":"T Jiang","year":"2020","unstructured":"Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N (2020) LMTK3 promotes tumorigenesis in bladder cancer via the ERK\/MAPK pathway. FEBS open bio 10(10):2107\u20132121. https:\/\/doi.org\/10.1002\/2211-5463.12964","journal-title":"FEBS open bio"},{"issue":"1","key":"11584_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1186\/s12967-024-06003-y","volume":"22","author":"T Tian","year":"2024","unstructured":"Tian T, He S, Hao H, Guan B, Gong Y, Fan J, Zhu Z, Gao W, Wu Y, Feng N, Wang A, Guo Y, Li X (2024) YWHAG promotes bladder cancer metastasis by regulating TMOD3 to activate ERK1\/2 and JNK phosphorylation in the MAPK pathway. J translational Med 22(1):1159. https:\/\/doi.org\/10.1186\/s12967-024-06003-y","journal-title":"J translational Med"},{"issue":"8","key":"11584_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander D, Clague MJ, Urb\u00e9 S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10(8):550\u2013563. https:\/\/doi.org\/10.1038\/nrm2731","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11584_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","volume":"78","author":"RJ Deshaies","year":"2009","unstructured":"Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399\u2013434. https:\/\/doi.org\/10.1146\/annurev.biochem.78.101807.093809","journal-title":"Annu Rev Biochem"},{"issue":"11","key":"11584_CR33","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.3739","volume":"20","author":"D Popovic","year":"2014","unstructured":"Popovic D, Vucic D, Dikic I (2014) Ubiquitination in disease pathogenesis and treatment. Nat Med 20(11):1242\u20131253. https:\/\/doi.org\/10.1038\/nm.3739","journal-title":"Nat Med"},{"issue":"7","key":"11584_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41419-023-05938-2","volume":"14","author":"K Xiao","year":"2023","unstructured":"Xiao K, Peng S, Lu J, Zhou T, Hong X, Chen S, Liu G, Li H, Huang J, Chen X, Lin T (2023) UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. Cell Death Dis 14(7):408. https:\/\/doi.org\/10.1038\/s41419-023-05938-2","journal-title":"Cell Death Dis"},{"issue":"13","key":"11584_CR35","doi-asserted-by":"publisher","first-page":"e179122","DOI":"10.1172\/JCI179122","volume":"134","author":"W Li","year":"2024","unstructured":"Li W, Chen C, Zheng H, Lin Y, An M, Liu D, Zhang Y, Gao M, Lan T, He W (2024) UBE2C-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer. J Clin Investig 134(13):e179122. https:\/\/doi.org\/10.1172\/JCI179122","journal-title":"J Clin Investig"},{"issue":"1","key":"11584_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41392-022-01152-2","volume":"7","author":"C Cai","year":"2022","unstructured":"Cai C, Tang YD, Zhai J, Zheng C (2022) The RING finger protein family in health and disease. Signal Transduct Target therapy 7(1):300. https:\/\/doi.org\/10.1038\/s41392-022-01152-2","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"11584_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13062-024-00562-2","volume":"19","author":"H Deng","year":"2024","unstructured":"Deng H, Ji G, Ma J, Cai J, Cheng S, Cheng F (2024) RNF19A inhibits bladder cancer progression by regulating ILK ubiquitination and inactivating the AKT\/mTOR signalling pathway. Biol Direct 19(1):102. https:\/\/doi.org\/10.1186\/s13062-024-00562-2","journal-title":"Biol Direct"},{"issue":"8","key":"11584_CR38","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.62347\/TECQ5002","volume":"14","author":"D Yao","year":"2024","unstructured":"Yao D, Xin F, He X (2024) RNF26-mediated ubiquitination of TRIM21 promotes bladder cancer progression. Am J cancer Res 14(8):4082\u20134095. https:\/\/doi.org\/10.62347\/TECQ5002","journal-title":"Am J cancer Res"},{"issue":"17","key":"11584_CR39","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.7150\/thno.101575","volume":"14","author":"M Li","year":"2024","unstructured":"Li M, Cui Y, Qi Q, Liu J, Li J, Huang G, Yang J, Sun J, Ma Z, Liang S, Zhang D, Jiang J, Zhu R, Liu Q, Huang R, Yan J (2024) SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3\/CCL2\/IL-6 axis and is regulated by VEZF1. Theranostics 14(17):6543\u20136559. https:\/\/doi.org\/10.7150\/thno.101575","journal-title":"Theranostics"},{"key":"11584_CR40","doi-asserted-by":"publisher","first-page":"217105","DOI":"10.1016\/j.canlet.2024.217105","volume":"598","author":"S Chen","year":"2024","unstructured":"Chen S, Zhao L, Liu J, Han P, Jiang W, Liu Y, Hou J, Wang F, Li J (2024) Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination. Cancer Lett 598:217105. https:\/\/doi.org\/10.1016\/j.canlet.2024.217105","journal-title":"Cancer Lett"},{"issue":"1","key":"11584_CR41","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1038\/s41467-023-38160-x","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Ju L, Wang G, Qian K, Jin W, Li M, Yu J, Shi Y, Wang Y, Zhang Y, Xiao Y, Wang X (2023) DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. Nat Commun 14(1):2421. https:\/\/doi.org\/10.1038\/s41467-023-38160-x","journal-title":"Nat Commun"},{"issue":"1","key":"11584_CR42","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12967-023-04311-3","volume":"21","author":"T Liu","year":"2023","unstructured":"Liu T, Fan MQ, Xie XX, Shu QP, Du XH, Qi LZ, Zhang XD, Zhang MH, Shan G, Du RL, Li SZ (2023) Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression. J translational Med 21(1):656. https:\/\/doi.org\/10.1186\/s12967-023-04311-3","journal-title":"J translational Med"},{"issue":"1","key":"11584_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12935-021-02095-4","volume":"21","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zhou J, Tang J, Zhou F, He Z, Liu T, Liu T (2021) MINDY1 promotes bladder cancer progression by stabilizing YAP. Cancer Cell Int 21(1):395. https:\/\/doi.org\/10.1186\/s12935-021-02095-4","journal-title":"Cancer Cell Int"},{"issue":"4","key":"11584_CR44","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3892\/ijo.2018.4280","volume":"52","author":"ZJ Han","year":"2018","unstructured":"Han ZJ, Feng YH, Gu BH, Li YM, Chen H (2018) The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol 52(4):1081\u20131094. https:\/\/doi.org\/10.3892\/ijo.2018.4280","journal-title":"Int J Oncol"},{"issue":"1","key":"11584_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrm3919","volume":"16","author":"RI Enchev","year":"2015","unstructured":"Enchev RI, Schulman BA, Peter M (2015) Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol 16(1):30\u201344. https:\/\/doi.org\/10.1038\/nrm3919","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"11584_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/0008-5472.CAN-23-2278","volume":"84","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Zheng H, Luo Y, An M, Lin Y, Pang M, Li Y, Kong Y, He W, Lin T, Chen C (2024) SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer. Cancer Res 84(3):434\u2013448. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2278","journal-title":"Cancer Res"},{"issue":"9\u201310","key":"11584_CR47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1101\/gad.316216.118","volume":"32","author":"Y Wan","year":"2018","unstructured":"Wan Y, Hopper AK (2018) Size matters: conserved proteins function in length-dependent nuclear export of circular RNAs. Genes Dev 32(9\u201310):600\u2013601. https:\/\/doi.org\/10.1101\/gad.316216.118","journal-title":"Genes Dev"},{"issue":"12","key":"11584_CR48","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1158\/0008-5472.CAN-21-4349","volume":"82","author":"M An","year":"2022","unstructured":"An M, Zheng H, Huang J, Lin Y, Luo Y, Kong Y, Pang M, Zhang D, Yang J, Chen J, Li Y, Chen C, Lin T (2022) Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer. Cancer Res 82(12):2239\u20132253. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4349","journal-title":"Cancer Res"},{"issue":"1","key":"11584_CR49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/cas.13865","volume":"110","author":"DW Tian","year":"2019","unstructured":"Tian DW, Wu ZL, Jiang LM, Gao J, Wu CL, Hu HL (2019) Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer. Cancer Sci 110(1):458\u2013467. https:\/\/doi.org\/10.1111\/cas.13865","journal-title":"Cancer Sci"},{"issue":"1","key":"11584_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s41065-025-00463-y","volume":"162","author":"H Xiaolong","year":"2025","unstructured":"Xiaolong H, Min D, Sizhou Z, Daorong H, Juncheng P, Yanjian W, Hong LJG, Ji Z, Qingjian W (2025) Prognostic analysis of bladder cancer with neddylation-related genes. Hereditas 162(1):105. https:\/\/doi.org\/10.1186\/s41065-025-00463-y","journal-title":"Hereditas"},{"issue":"12","key":"11584_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","volume":"21","author":"KT Schjoldager","year":"2020","unstructured":"Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H (2020) Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol 21(12):729\u2013749. https:\/\/doi.org\/10.1038\/s41580-020-00294-x","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"11584_CR52","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15(9):540\u2013555. https:\/\/doi.org\/10.1038\/nrc3982","journal-title":"Nat Rev Cancer"},{"key":"11584_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","volume":"10","author":"SR Stowell","year":"2015","unstructured":"Stowell SR, Ju T, Cummings RD (2015) Protein glycosylation in cancer. Annu Rev Pathol 10:473\u2013510. https:\/\/doi.org\/10.1146\/annurev-pathol-012414-040438","journal-title":"Annu Rev Pathol"},{"key":"11584_CR54","doi-asserted-by":"publisher","first-page":"216258","DOI":"10.1016\/j.canlet.2023.216258","volume":"566","author":"XF He","year":"2023","unstructured":"He XF, Hu X, Wen GJ, Wang Z, Lin WJ (2023) O-GlcNAcylation in cancer development and immunotherapy. Cancer Lett 566:216258. https:\/\/doi.org\/10.1016\/j.canlet.2023.216258","journal-title":"Cancer Lett"},{"issue":"1","key":"11584_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41401-022-00934-2","volume":"44","author":"HF Wang","year":"2023","unstructured":"Wang HF, Wang YX, Zhou YP, Wei YP, Yan Y, Zhang ZJ, Jing ZC (2023) Protein O-GlcNAcylation in cardiovascular diseases. Acta Pharmacol Sin 44(1):8\u201318. https:\/\/doi.org\/10.1038\/s41401-022-00934-2","journal-title":"Acta Pharmacol Sin"},{"issue":"30","key":"11584_CR56","doi-asserted-by":"publisher","first-page":"e2202993","DOI":"10.1002\/advs.202202993","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, Guo H, He W, Zhou X, Gou X (2022) Bladder Cancer-Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP-Related Metabolic Reprogramming and SerRS O-GlcNAcylation in Endothelial Cells. Adv Sci (Weinheim Baden-Wurttemberg Germany) 9(30):e2202993. https:\/\/doi.org\/10.1002\/advs.202202993","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"8","key":"11584_CR57","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3724\/abbs.2024129","volume":"56","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wu J, Guan F, Liang L, Wang Y (2024) O-GlcNAcylation determines the function of the key O-GalNAc glycosyltransferase C1GalT1 in bladder cancer. Acta Biochim Biophys Sin 56(8):1108\u20131117. https:\/\/doi.org\/10.3724\/abbs.2024129","journal-title":"Acta Biochim Biophys Sin"},{"key":"11584_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s11658-020-00208-x","volume":"25","author":"L Jin","year":"2020","unstructured":"Jin L, Yuan F, Dai G, Yao Q, Xiang H, Wang L, Xue B, Shan Y, Liu X (2020) Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett 25:17. https:\/\/doi.org\/10.1186\/s11658-020-00208-x","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"11584_CR59","doi-asserted-by":"publisher","first-page":"e12765","DOI":"10.1111\/jpi.12765","volume":"71","author":"J Wu","year":"2021","unstructured":"Wu J, Tan Z, Li H, Lin M, Jiang Y, Liang L, Ma Q, Gou J, Ning L, Li X, Guan F (2021) Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5. J Pineal Res 71(3):e12765. https:\/\/doi.org\/10.1111\/jpi.12765","journal-title":"J Pineal Res"},{"key":"11584_CR60","doi-asserted-by":"publisher","first-page":"122471","DOI":"10.1016\/j.carbpol.2024.122471","volume":"343","author":"X Ma","year":"2024","unstructured":"Ma X, Li M, Wang X, Qi G, Wei L, Zhang D (2024) Sialylation in the gut: From mucosal protection to disease pathogenesis. Carbohydr Polym 343:122471. https:\/\/doi.org\/10.1016\/j.carbpol.2024.122471","journal-title":"Carbohydr Polym"},{"issue":"8","key":"11584_CR61","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.3390\/molecules28083436","volume":"28","author":"M Wilczak","year":"2023","unstructured":"Wilczak M, Surman M, Przyby\u0142o M (2023) Altered Glycosylation in Progression and Management of Bladder Cancer. Molecules 28(8):3436. https:\/\/doi.org\/10.3390\/molecules28083436","journal-title":"Molecules"},{"issue":"1","key":"11584_CR62","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/s41467-025-57633-9","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Fu B, Wang M, Chen W, Fan J, Li Y, Liu X, Wang J, Zhang Z, Lu H, Zhang Y (2025) Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer. Nat Commun 16(1):2292. https:\/\/doi.org\/10.1038\/s41467-025-57633-9","journal-title":"Nat Commun"},{"key":"11584_CR63","doi-asserted-by":"publisher","first-page":"112569","DOI":"10.1016\/j.intimp.2024.112569","volume":"138","author":"Y Jian","year":"2024","unstructured":"Jian Y, Chen Q, Al-Danakh A, Xu Z, Xu C, Sun X, Yu X, Yang D, Wang S (2024) Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis. Int Immunopharmacol 138:112569. https:\/\/doi.org\/10.1016\/j.intimp.2024.112569","journal-title":"Int Immunopharmacol"},{"issue":"22","key":"11584_CR64","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.7150\/thno.48711","volume":"10","author":"S Dalangood","year":"2020","unstructured":"Dalangood S, Zhu Z, Ma Z, Li J, Zeng Q, Yan Y, Shen B, Yan J, Huang R (2020) Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics 10(22):10078\u201310091. https:\/\/doi.org\/10.7150\/thno.48711","journal-title":"Theranostics"},{"issue":"5","key":"11584_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.chembiol.2018.02.005","volume":"25","author":"J Li","year":"2018","unstructured":"Li J, Hsu HC, Mountz JD, Allen JG (2018) Unmasking Fucosylation: from Cell Adhesion to Immune System Regulation and Diseases. Cell Chem biology 25(5):499\u2013512. https:\/\/doi.org\/10.1016\/j.chembiol.2018.02.005","journal-title":"Cell Chem biology"},{"issue":"1","key":"11584_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1042\/BJ20131424","volume":"460","author":"YC Lu","year":"2014","unstructured":"Lu YC, Chen CN, Chu CY, Lu J, Wang BJ, Chen CH, Huang MC, Lin TH, Pan CC, Chen SS, Hsu WM, Liao YF, Wu PY, Hsia HY, Chang CC, Lee H (2014) Calreticulin activates \u03b21 integrin via fucosylation by fucosyltransferase 1 in J82 human bladder cancer cells. Biochem J 460(1):69\u201378. https:\/\/doi.org\/10.1042\/BJ20131424","journal-title":"Biochem J"},{"key":"11584_CR67","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2147\/JIR.S296597","volume":"14","author":"M Liu","year":"2021","unstructured":"Liu M, Zheng Q, Chen S, Liu J, Li S (2021) FUT7 Promotes the Epithelial-Mesenchymal Transition and Immune Infiltration in Bladder Urothelial Carcinoma. J Inflamm Res 14:1069\u20131084. https:\/\/doi.org\/10.2147\/JIR.S296597","journal-title":"J Inflamm Res"},{"issue":"19","key":"11584_CR68","doi-asserted-by":"publisher","first-page":"11308","DOI":"10.3390\/ijms231911308","volume":"23","author":"M Xue","year":"2022","unstructured":"Xue M, Feng T, Chen Z, Yan Y, Chen Z, Dai J (2022) Protein Acetylation Going Viral: Implications in Antiviral Immunity and Viral Infection. Int J Mol Sci 23(19):11308. https:\/\/doi.org\/10.3390\/ijms231911308","journal-title":"Int J Mol Sci"},{"issue":"5","key":"11584_CR69","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1002\/ctm2.738","volume":"12","author":"G Wang","year":"2022","unstructured":"Wang G, Zhang M, Zhang Y, Xie Y, Zou J, Zhong J, Zheng Z, Zhou X, Zheng Y, Chen B, Liu C (2022) NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression. Clin translational Med 12(5):e738. https:\/\/doi.org\/10.1002\/ctm2.738","journal-title":"Clin translational Med"},{"issue":"7788","key":"11584_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-019-1842-7","volume":"577","author":"L Wan","year":"2020","unstructured":"Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, Carroll TS, Li Y, Feng L, Chen G, Wang SP, Ortiz MV, Daley SK, Wang X, Xuan H, Kentsis A, Muir TW, Roeder RG, Li H, Li W, Allis CD (2020) Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature 577(7788):121\u2013126. https:\/\/doi.org\/10.1038\/s41586-019-1842-7","journal-title":"Nature"},{"issue":"3","key":"11584_CR71","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cell.2014.09.049","volume":"159","author":"Y Li","year":"2014","unstructured":"Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, Ren Y, Jin Q, Dent SY, Li W, Li H, Shi X (2014) AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159(3):558\u2013571. https:\/\/doi.org\/10.1016\/j.cell.2014.09.049","journal-title":"Cell"},{"issue":"22","key":"11584_CR72","doi-asserted-by":"publisher","first-page":"e2310146","DOI":"10.1002\/advs.202310146","volume":"11","author":"M Xie","year":"2024","unstructured":"Xie M, Zhou L, Li T, Lin Y, Zhang R, Zheng X, Zeng C, Zheng L, Zhong L, Huang X, Zou Y, Kang T, Wu Y (2024) Targeting the KAT8\/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer. Adv Sci (Weinheim Baden-Wurttemberg Germany) 11(22):e2310146. https:\/\/doi.org\/10.1002\/advs.202310146","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"1","key":"11584_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41419-025-07645-6","volume":"16","author":"Z Lin","year":"2025","unstructured":"Lin Z, Liang F, Hong G, Jiang X, Zhang Q, Wang M (2025) TACC3 enhances glycolysis in bladder cancer cells through inducing acetylation of c-Myc. Cell Death Dis 16(1):311. https:\/\/doi.org\/10.1038\/s41419-025-07645-6","journal-title":"Cell Death Dis"},{"key":"11584_CR74","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2021.4","volume":"23","author":"X Dai","year":"2021","unstructured":"Dai X, Ren T, Zhang Y, Nan N (2021) Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med 23:e2. https:\/\/doi.org\/10.1017\/erm.2021.4","journal-title":"Expert Rev Mol Med"},{"issue":"9","key":"11584_CR75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","volume":"23","author":"G Mill\u00e1n-Zambrano","year":"2022","unstructured":"Mill\u00e1n-Zambrano G, Burton A, Bannister AJ, Schneider R (2022) Histone post-translational modifications - cause and consequence of genome function. Nat Rev Genet 23(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41576-022-00468-7","journal-title":"Nat Rev Genet"},{"issue":"4","key":"11584_CR76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR (2012) Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 48(4):491\u2013507. https:\/\/doi.org\/10.1016\/j.molcel.2012.11.006","journal-title":"Mol Cell"},{"issue":"1","key":"11584_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-021-01369-9","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia Y, Wang Y, Chen S, Sun S, Shi B, Zou Y (2021) KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer 20(1):77. https:\/\/doi.org\/10.1186\/s12943-021-01369-9","journal-title":"Mol Cancer"},{"issue":"1","key":"11584_CR78","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41467-018-06152-x","volume":"9","author":"C Chen","year":"2018","unstructured":"Chen C, He W, Huang J, Wang B, Li H, Cai Q, Su F, Bi J, Liu H, Zhang B, Jiang N, Zhong G, Zhao Y, Dong W, Lin T (2018) LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun 9(1):3826. https:\/\/doi.org\/10.1038\/s41467-018-06152-x","journal-title":"Nat Commun"},{"key":"11584_CR79","doi-asserted-by":"publisher","first-page":"195","DOI":"10.17179\/excli2018-1807","volume":"18","author":"N Coban","year":"2019","unstructured":"Coban N, Varol N (2019) The effect of heat shock protein 90 inhibitors on histone 4 lysine 20 methylation in bladder cancer. EXCLI J 18:195\u2013203. https:\/\/doi.org\/10.17179\/excli2018-1807","journal-title":"EXCLI J"},{"key":"11584_CR80","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2147\/IJN.S228839","volume":"15","author":"T Zhang","year":"2020","unstructured":"Zhang T, Du E, Liu Y, Cheng J, Zhang Z, Xu Y, Qi S, Chen Y (2020) Anticancer Effects of Zinc Oxide Nanoparticles Through Altering the Methylation Status of Histone on Bladder Cancer Cells. Int J Nanomed 15:1457\u20131468. https:\/\/doi.org\/10.2147\/IJN.S228839","journal-title":"Int J Nanomed"},{"issue":"1","key":"11584_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-024-01759-7","volume":"9","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Li P, Li J, Zhao Q, Chang Y, He X (2024) Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal Transduct Target therapy 9(1):60. https:\/\/doi.org\/10.1038\/s41392-024-01759-7","journal-title":"Signal Transduct Target therapy"},{"key":"11584_CR82","doi-asserted-by":"publisher","first-page":"114915","DOI":"10.1016\/j.biopha.2023.114915","volume":"164","author":"D Jung","year":"2023","unstructured":"Jung D, Bachmann HS (2023) Regulation of protein prenylation. Biomed pharmacotherapy = Biomedecine pharmacotherapie 164:114915. https:\/\/doi.org\/10.1016\/j.biopha.2023.114915","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"3","key":"11584_CR83","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3892\/mmr.2015.3995","volume":"12","author":"X Wang","year":"2015","unstructured":"Wang X, Wu G, Cao G, Yang L, Xu H, Huang J, Hou J (2015) Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells. Mol Med Rep 12(3):4620\u20134625. https:\/\/doi.org\/10.3892\/mmr.2015.3995","journal-title":"Mol Med Rep"},{"issue":"1","key":"11584_CR84","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cancers3010662","volume":"3","author":"S Li","year":"2011","unstructured":"Li S, De Souza P (2011) Ras Isoprenylation and pAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells. Cancers 3(1):662\u2013674. https:\/\/doi.org\/10.3390\/cancers3010662","journal-title":"Cancers"},{"issue":"10","key":"11584_CR85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cac2.12602","volume":"44","author":"M Noeraparast","year":"2024","unstructured":"Noeraparast M, Krajina K, Pichler R, Nieders\u00fc\u00df-Beke D, Shariat SF, Gr\u00fcnwald V, Ahyai S, Pichler M (2024) FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer Commun (London England) 44(10):1189\u20131208. https:\/\/doi.org\/10.1002\/cac2.12602","journal-title":"Cancer Commun (London England)"},{"issue":"4","key":"11584_CR86","doi-asserted-by":"publisher","first-page":"e8163","DOI":"10.15252\/emmm.201708163","volume":"10","author":"M Mahe","year":"2018","unstructured":"Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, Hamaidi I, Sanchez-Quiles V, Krucker C, Dorland-Galliot M, Chapeaublanc E, Nicolle R, Lang H, Pouponnot C, Massfelder T, Radvanyi F, Bernard-Pierrot I (2018) An FGFR3\/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med 10(4):e8163. https:\/\/doi.org\/10.15252\/emmm.201708163","journal-title":"EMBO Mol Med"},{"issue":"1","key":"11584_CR87","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, Li W, Han B, Chen S, Shi B (2022) FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. Cancer Res 82(1):114\u2013129. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2362","journal-title":"Cancer Res"},{"key":"11584_CR88","doi-asserted-by":"publisher","first-page":"154536","DOI":"10.1016\/j.prp.2023.154536","volume":"247","author":"LJ Jiang","year":"2023","unstructured":"Jiang LJ, Guo SB, Huang ZY, Li XL, Jin XH, Huang WJ, Tian XP (2023) PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt\/\u03b2-catenin signaling pathway. Pathol Res Pract 247:154536. https:\/\/doi.org\/10.1016\/j.prp.2023.154536","journal-title":"Pathol Res Pract"},{"key":"11584_CR89","doi-asserted-by":"publisher","first-page":"114962","DOI":"10.1016\/j.biopha.2023.114962","volume":"164","author":"CJ Yang","year":"2023","unstructured":"Yang CJ, Tan ZL, Yang JD, Hsu FT, Chiang CH (2023) Fluoxetine inactivates STAT3\/NF-\u03baB signaling and promotes sensitivity to cisplatin in bladder cancer. Biomed pharmacotherapy = Biomedecine pharmacotherapie 164:114962. https:\/\/doi.org\/10.1016\/j.biopha.2023.114962","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"1","key":"11584_CR90","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-021-01935-5","volume":"40","author":"Q Wu","year":"2021","unstructured":"Wu Q, Zhou X, Li P, Ding M, You S, Xu Z, Ye J, Chen X, Tan M, Wang J, Wang W, Qiu J (2021) ROC1 promotes the malignant progression of bladder cancer by regulating p-I\u03baB\u03b1\/NF-\u03baB signaling. J experimental Clin cancer research: CR 40(1):158. https:\/\/doi.org\/10.1186\/s13046-021-01935-5","journal-title":"J experimental Clin cancer research: CR"},{"key":"11584_CR91","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.17179\/excli2018-1719","volume":"17","author":"G Hu","year":"2018","unstructured":"Hu G, Wang X, Han Y, Wang P (2018) Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis. EXCLI J 17:1157\u20131166. https:\/\/doi.org\/10.17179\/excli2018-1719","journal-title":"EXCLI J"},{"issue":"3","key":"11584_CR92","doi-asserted-by":"publisher","first-page":"108276","DOI":"10.1016\/j.celrep.2020.108276","volume":"33","author":"Y Hu","year":"2020","unstructured":"Hu Y, Pan J, Shah P, Ao M, Thomas SN, Liu Y, Chen L, Schnaubelt M, Clark DJ, Rodriguez H, Boja ES, Hiltke T, Kinsinger CR, Rodland KD, Li QK, Qian J, Zhang Z, Chan DW, Zhang H, Clinical Proteomic Tumor Analysis Consortium (2020) Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. Cell Rep 33(3):108276. https:\/\/doi.org\/10.1016\/j.celrep.2020.108276","journal-title":"Cell Rep"},{"issue":"1","key":"11584_CR93","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/s41467-020-19976-3","volume":"11","author":"J Pan","year":"2020","unstructured":"Pan J, Hu Y, Sun S, Chen L, Schnaubelt M, Clark D, Ao M, Zhang Z, Chan D, Qian J, Zhang H (2020) Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer. Nat Commun 11(1):6139. https:\/\/doi.org\/10.1038\/s41467-020-19976-3","journal-title":"Nat Commun"},{"key":"11584_CR94","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.ejmech.2024.116129","volume":"265","author":"B Cheng","year":"2024","unstructured":"Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, Liu J, Su Z, Peng X, Chen J (2024) HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem 265:116129. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116129","journal-title":"Eur J Med Chem"},{"issue":"66","key":"11584_CR95","doi-asserted-by":"publisher","first-page":"110016","DOI":"10.18632\/oncotarget.22454","volume":"8","author":"E Juengel","year":"2017","unstructured":"Juengel E, Najafi R, Rutz J, Maxeiner S, Makarevic J, Roos F, Tsaur I, Haferkamp A, Blaheta RA (2017) HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget 8(66):110016\u2013110028. https:\/\/doi.org\/10.18632\/oncotarget.22454","journal-title":"Oncotarget"},{"issue":"11","key":"11584_CR96","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1177\/1535370213498975","volume":"238","author":"E Juengel","year":"2013","unstructured":"Juengel E, Meyer dos Santos S, Schneider T, Makarevic J, Hudak L, Bartsch G, Haferkamp A, Wiesner C, Blaheta RA (2013) HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. Experimental biology Med (Maywood N J) 238(11):1297\u20131304. https:\/\/doi.org\/10.1177\/1535370213498975","journal-title":"Experimental biology Med (Maywood N J)"},{"key":"11584_CR97","doi-asserted-by":"publisher","first-page":"103407","DOI":"10.1016\/j.redox.2024.103407","volume":"77","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xu H, He Y, Zheng X, Lin T, Yang L, Tan P, Wei Q (2024) Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer. Redox Biol 77:103407. https:\/\/doi.org\/10.1016\/j.redox.2024.103407","journal-title":"Redox Biol"},{"issue":"1","key":"11584_CR98","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2017.03.021","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, \u00d8rum-Madsen MS, Agerb\u00e6k M\u00d8, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenh\u00f6fer T, Esfandnia S, Battsogt D, Babcook JS, Daugaard M (2017) An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. Eur Urol 72(1):142\u2013150. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.021","journal-title":"Eur Urol"},{"issue":"8052","key":"11584_CR99","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-025-08584-0","volume":"638","author":"T Guo","year":"2025","unstructured":"Guo T, Steen JA, Mann M (2025) Mass-spectrometry-based proteomics: from single cells to clinical applications. Nature 638(8052):901\u2013911. https:\/\/doi.org\/10.1038\/s41586-025-08584-0","journal-title":"Nature"},{"key":"11584_CR100","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.actbio.2025.03.032","volume":"197","author":"J Xu","year":"2025","unstructured":"Xu J, Xu J, Sun C, He X, Shu Y, Huangfu Q, Meng L, Liang Z, Wei J, Cai M, Wen J, Wang B (2025) Effective delivery of CRISPR\/dCas9-SAM for multiplex gene activation based on mesoporous silica nanoparticles for bladder cancer therapy. Acta Biomater 197:460\u2013475. https:\/\/doi.org\/10.1016\/j.actbio.2025.03.032","journal-title":"Acta Biomater"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11584-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:44:44Z","timestamp":1772196284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11584"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11584-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}